Physician profile
Bryan D Vo
NPI 1477903961
$5,569.73
in general payments reported to CMS, 2019-2025
50 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $476 · 2021: $38.34 · 2022: $1,361 · 2023: $584 · 2024: $1,383 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,319 · Honoraria: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,318.76 |
| Honoraria | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $651.27 | 2024-2025 | Inspire |
| Lilly USA, LLC | $613.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $527.53 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $449.67 | 2020-2025 | Airsupra, Fasenra, Breztri |
| Pfizer INC. | $263.22 | 2019-2025 | |
| Abbvie INC. | $261.20 | 2022-2025 | Vraylar |
| Amgen INC. | $245.87 | 2019-2025 | Repatha, Otezla, Repatha |
| Noven Therapeutics, LLC | $229.22 | 2024-2025 | Xelstrym |
| Neos Therapeutics, LP | $173.69 | 2022 | |
| Astellas Pharma US INC | $169.46 | 2020-2025 | Veozah |
| Axsome Therapeutics, INC. | $134.54 | 2022-2025 | Sunosi, Auvelity |
| Exact Sciences Corporation | $133.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $129.80 | 2020-2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.67 | 2020-2025 | Ofev |
| Biohaven Pharmaceutical Holding Company LTD. | $107.88 | 2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.